



Supplementary Figure 1


A



B




C



Supplementary Figure 1. ULBP1 expression correlates with better outcome in a stepwise manner.

Kaplan–Meier estimates of overall survival (A), cumulative incidence of relapse (B) and relapse free survival (C), according to ULBP1 relative fluorescence intensity score: patients belonging to score 0 (non expressors), 1 (low expressors) and 2 (high expressors) are represented by black, red and green lines, respectively. P values are shown.

Supplementary Figure 2



Supplementary Figure 2. Overall survival of our patient population according to cytogenetic and molecular risk. Kaplan–Meier estimates of overall survival in our cohort of patients, according to cytogenetic risk (left panel) and ELN classification (right panel): patients belonging to favorable, intermediate and adverse risk groups are represented by black, red and green lines, respectively. *P* values are shown.

Supplementary Table 1

	OS			RFS			CIR		
	HR	95% CI	<i>P</i>	HR	95% CI	<i>P</i>	HR	95% CI	<i>P</i>
MICA	0.65	0.291-1.442	0.288	0.60	0.299-1.196	0.146	0.52	0.217-1.25	0.140
MICB	0.79	0.403-1.564	0.505	0.79	0.423-1.474	0.458	0.61	0.273-1.34	0.220
CD155	0.76	0.267-2.148	0.601	0.77	0.301-1.957	0.580	0.78	0.23-2.66	0.690
CD112	0.78	0.336-1.796	0.555	0.74	0.350-1.542	0.415	0.52	0.196-1.4	0.200
ULBP1	0.34	0.161-0.732	0.006	0.42	0.200-0.865	0.019	0.35	0.169-0.726	0.005
ULBP2/5/6	0.76	0.387-1.496	0.428	0.87	0.473-1.601	0.655	0.52	0.23-1.18	0.120
HLA-1	1.36	0.666-2.757	0.402	1.18	0.607-2.31	0.620	1.61	0.679-3.81	0.280
PD-L1	1.06	0.521-2.166	0.867	0.90	0.459-1.75	0.749	0.39	0.157-0.977	0.044
PD-L2	1.14	0.515-2.506	0.752	1.27	0.605-2.662	0.528	2.01	0.842-4.79	0.120

Supplementary Table 1. Univariate correlation between the expression of each individual NK receptor ligand and patient outcome. OS indicates overall survival, RFS relapse free survival, CIR cumulative incidence of relapse, HR hazard ratio, CI confidence interval, *P* P value.